Orgenesis Inc. Announces Pricing of 1.1 Million Registered Direct Offering
| ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Slightly above 62% of Orgenesis' investor base is looking to short. The analysis of overall sentiment of trading Orgenesis otc stock suggests that many investors are alarmed at this time. Orgenesis' investing sentiment can be driven by a variety of factors including economic data, Orgenesis' earnings reports, geopolitical events, and overall market trends.
Orgenesis otc stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Orgenesis daily returns and investor perception about the current price of Orgenesis as well as its diversification or hedging effects on your existing portfolios.
Orgenesis |
GERMANTOWN, Md., Nov. 08, 2023 -- Orgenesis Inc. , a global biotech company working to unlock the full potential of cell and gene therapies , announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately 1.1 million of its common stock and warrants to purchase common stock in a registered direct offering. The combined effective purchase price for each share of common stoc
Read at finance.yahoo.com
 |
Orgenesis Fundamental Analysis
We analyze Orgenesis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Orgenesis is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Orgenesis Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Orgenesis otc stock to make a market-neutral strategy. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics with similar companies.
Peers
Orgenesis Related Equities
| INDP | Indaptus Therapeutics | 5.62 | ||||
| TNGX | Tango Therapeutics | 5.44 | ||||
| DSGN | Design Therapeutics | 4.34 | ||||
| RZLT | Rezolute | 3.78 | ||||
| LIXT | Lixte Biotechnology | 3.66 | ||||
| ADAG | Adagene | 1.99 | ||||
| ACHL | Achilles Therapeutics | 1.03 | ||||
| ACRV | Acrivon Therapeutics, | 0.30 | ||||
| ANTX | AN2 Therapeutics | 0.79 | ||||
| AVTE | Aerovate Therapeutics | 1.17 | ||||
| KTTA | Pasithea Therapeutics | 1.50 | ||||
| QNRX | Quoin Pharmaceuticals | 12.31 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |